Targovax signs clinical collaboration agreement with the Parker Institute for Cancer Immunotherapy and Cancer Research Institute
· The parties plan to conduct a clinical collaboration trial with Targovax TG mutant RAS vaccine · The collaboration will focus on testing TG vaccination in combination with other treatments in late stage pancreatic cancer Oslo, Norway, 15 March 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that it has entered into an agreement with The Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI) for a clinical collaboration with Targovax’ TG mutant